These findings are in line with previous work implicating a role for host NLRP3 in suppressing the efficacy of a dendritic cell-based cancer vaccine by recruiting CD11b+Gr-1+ MDSCs into tumor tissues [29]. Here, NLRP3 is linked to cancer.